DE60234269D1 - Substituierte aryl 1,4-pyrazin derivate - Google Patents
Substituierte aryl 1,4-pyrazin derivateInfo
- Publication number
- DE60234269D1 DE60234269D1 DE60234269T DE60234269T DE60234269D1 DE 60234269 D1 DE60234269 D1 DE 60234269D1 DE 60234269 T DE60234269 T DE 60234269T DE 60234269 T DE60234269 T DE 60234269T DE 60234269 D1 DE60234269 D1 DE 60234269D1
- Authority
- DE
- Germany
- Prior art keywords
- substituted aryl
- pyrazine derivatives
- pyrazine
- derivatives
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5751—Corticotropin releasing factor [CRF] (Urotensin)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Luminescent Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33205201P | 2001-11-21 | 2001-11-21 | |
US35854602P | 2002-02-21 | 2002-02-21 | |
US33828502P | 2002-06-13 | 2002-06-13 | |
US41037802P | 2002-09-13 | 2002-09-13 | |
PCT/US2002/033642 WO2003045924A1 (fr) | 2001-11-21 | 2002-11-15 | Derives d'aryle-1,4-pyrazine substitues |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60234269D1 true DE60234269D1 (de) | 2009-12-17 |
Family
ID=27502457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60234269T Expired - Lifetime DE60234269D1 (de) | 2001-11-21 | 2002-11-15 | Substituierte aryl 1,4-pyrazin derivate |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1446387B1 (fr) |
AT (1) | ATE447561T1 (fr) |
AU (1) | AU2002343557A1 (fr) |
BR (1) | BR0214309A (fr) |
CA (1) | CA2467870A1 (fr) |
DE (1) | DE60234269D1 (fr) |
DK (1) | DK1446387T3 (fr) |
ES (1) | ES2333586T3 (fr) |
MX (1) | MXPA04004714A (fr) |
PT (1) | PT1446387E (fr) |
WO (1) | WO2003045924A1 (fr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
PT2476667E (pt) | 2003-02-26 | 2014-09-18 | Sugen Inc | Compostos de aminoheteroarilo como inibidores da proteína quinase |
JP2006525993A (ja) | 2003-05-09 | 2006-11-16 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Crf1受容体拮抗剤である化合物 |
DE502004002403D1 (de) | 2003-10-08 | 2007-02-01 | Schering Ag | Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer |
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
WO2005040135A1 (fr) * | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | Medicament antistress et usage medical correspondant |
EP1678160A1 (fr) * | 2003-10-27 | 2006-07-12 | Astellas Pharma Inc. | Derives de pyrazine et utilisation pharmaceutique de ce derive |
AU2004297235A1 (en) * | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
US20080153859A1 (en) | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US20080269249A2 (en) * | 2004-12-27 | 2008-10-30 | Alcon, Inc. | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions |
US20060211710A1 (en) * | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
DE102005017316A1 (de) * | 2005-04-14 | 2006-10-19 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
NL2000284C2 (nl) * | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
EP1834948A1 (fr) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Derives de tetrahydronaphtalene , procedes pour leur production et leur utilisation en tant qu'anti-inflammatoires |
JP2009532356A (ja) * | 2006-03-31 | 2009-09-10 | シェーリング コーポレイション | キナーゼ阻害物質 |
US8653100B2 (en) | 2008-04-01 | 2014-02-18 | Abbvie Inc. | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
MX2011004953A (es) | 2008-11-10 | 2011-12-14 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
KR101745331B1 (ko) | 2008-12-19 | 2017-06-09 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 피라진 유도체 |
AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
WO2011143423A2 (fr) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2012013082A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr. |
EP2569289A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines utiles en tant qu'inhibiteurs de la kinase atr |
EP2569287B1 (fr) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP2694498B1 (fr) | 2011-04-05 | 2016-03-30 | Vertex Pharmaceuticals Incorporated | Composés aminopyrazines utiles comme inhibiteurs de la kinase tra |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
WO2012178124A1 (fr) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de la kinase atr |
EP2723746A1 (fr) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Composés inhibiteurs de la kinase atr |
JP2014520161A (ja) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
US8853196B2 (en) | 2011-08-05 | 2014-10-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2751088B1 (fr) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
KR102184246B1 (ko) | 2011-09-30 | 2020-12-01 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 화합물의 제조 방법 |
CA2850564A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composes utiles comme inhibiteurs de kinase atr |
BR112014007690B1 (pt) | 2011-09-30 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas |
WO2013071094A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071093A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés de pyrazine utiles comme inhibiteurs de kinase atr |
WO2013071090A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
RS56673B1 (sr) | 2012-04-05 | 2018-03-30 | Vertex Pharma | Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste |
US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN107501275B (zh) | 2012-12-07 | 2019-11-22 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物 |
JP6307096B2 (ja) | 2013-01-23 | 2018-04-04 | アストラゼネカ アクチボラグ | 化合物 |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP2970286A1 (fr) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr |
CN105992764A (zh) | 2013-10-17 | 2016-10-05 | 艾伯维德国有限责任两合公司 | 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物,包含其的药物组合物及其在治疗中的用途 |
JP2016533375A (ja) | 2013-10-17 | 2016-10-27 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用 |
RU2720408C2 (ru) | 2013-12-06 | 2020-04-29 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения ингибиторов atr киназы (варианты) |
AU2015271030B2 (en) | 2014-06-05 | 2019-05-16 | Vertex Pharmaceuticals Incorporated | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof |
ES2733847T3 (es) | 2014-06-17 | 2019-12-03 | Vertex Pharma | Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR |
WO2017059357A1 (fr) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr |
CN109983001B (zh) | 2016-07-12 | 2023-04-04 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
IL296456A (en) | 2017-01-23 | 2022-11-01 | Revolution Medicines Inc | Bicyclics as allosteric shp2 inhibitors |
BR112019014527A2 (pt) | 2017-01-23 | 2020-02-27 | Revolution Medicines, Inc. | Compostos de piridina como inibidores de shp2 alostéricos |
JP6957598B2 (ja) * | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
AU2018347516A1 (en) | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
SG11202004090YA (en) | 2017-12-15 | 2020-05-28 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH061776A (ja) * | 1992-06-18 | 1994-01-11 | Nippon Soda Co Ltd | 置換ピラジンカルボニトリルの製造方法 |
MA26473A1 (fr) * | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
EE200200453A (et) * | 2000-02-16 | 2003-12-15 | Neurogen Corporation | Asendatud arüülpürasiinid |
-
2002
- 2002-11-15 PT PT02780507T patent/PT1446387E/pt unknown
- 2002-11-15 EP EP02780507A patent/EP1446387B1/fr not_active Expired - Lifetime
- 2002-11-15 DE DE60234269T patent/DE60234269D1/de not_active Expired - Lifetime
- 2002-11-15 CA CA002467870A patent/CA2467870A1/fr not_active Abandoned
- 2002-11-15 AU AU2002343557A patent/AU2002343557A1/en not_active Abandoned
- 2002-11-15 MX MXPA04004714A patent/MXPA04004714A/es active IP Right Grant
- 2002-11-15 AT AT02780507T patent/ATE447561T1/de not_active IP Right Cessation
- 2002-11-15 DK DK02780507T patent/DK1446387T3/da active
- 2002-11-15 WO PCT/US2002/033642 patent/WO2003045924A1/fr active Application Filing
- 2002-11-15 BR BR0214309-7A patent/BR0214309A/pt not_active IP Right Cessation
- 2002-11-15 ES ES02780507T patent/ES2333586T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1446387B1 (fr) | 2009-11-04 |
WO2003045924A1 (fr) | 2003-06-05 |
EP1446387A1 (fr) | 2004-08-18 |
BR0214309A (pt) | 2004-10-13 |
ATE447561T1 (de) | 2009-11-15 |
DK1446387T3 (da) | 2009-12-21 |
MXPA04004714A (es) | 2004-08-19 |
PT1446387E (pt) | 2009-12-21 |
ES2333586T3 (es) | 2010-02-24 |
CA2467870A1 (fr) | 2003-06-05 |
AU2002343557A1 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE447561T1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
MY130489A (en) | Substituted aryl 1, 4-pyrazine derivatives | |
ATE294171T1 (de) | Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung | |
CY1115441T1 (el) | Αναστολεις p38 και μεθοδοι χρησης αυτων | |
NO20034056D0 (no) | Proliferative sykdommer | |
DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
CY1107924T1 (el) | Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης | |
CY1107054T1 (el) | Ενωσεις διτοσυλικου αλατος κιναζολινης | |
CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
NO20055516L (no) | Kannabinoidreceptorligander og anvendelser derav | |
TR200002773T2 (tr) | Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı. | |
CY1112946T1 (el) | 4-υδροξυβενζομορφανια | |
ATE341537T1 (de) | Dolastatin 10 derivate | |
DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
NO20034364L (no) | Sapogenin-derivater, deres syntese og anvendelse samt metoder basert pa deres anvendelse | |
NO20043085L (no) | Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet | |
ATE265454T1 (de) | Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung | |
ATE365748T1 (de) | Polymer-konjugate von neublastin und methoden für deren verwendung | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
DK1220852T3 (da) | Substituerede diazepaner | |
TW200503717A (en) | Substituted 1,4-pyrazine derivatives | |
ATE383874T1 (de) | Perylenequinonen zur anwendung als sonosensitizer | |
NO20060420L (no) | 2-aminobenzoylderivater | |
DE60315288D1 (de) | Cyanoguanidin prodrugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |